Manhattan BioSolutions Selected for MSK Therapeutics Accelerator Cohort

NEW YORK - Oct. 10, 2025 - PRLog -- Manhattan BioSolutions, Inc. ("Manhattan Bio" or "MABS"), an emerging biotechnology company developing new classes of precision biologics, today announced its selection for Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator 2025 Cohort Program. This selective program connects innovative biotech companies with MSK's world-class clinical and translational experts to explore potential collaboration pathways for advancing novel cancer therapeutics.

As one of the world's foremost cancer research and treatment institutions, MSK has more than 135 years of leadership in patient care, education, and discovery. Through the MSK Therapeutics Accelerator Cohort program, Manhattan Bio is engaging with MSK clinicians and translational scientists to explore potential synergies for advancing the company's proprietary legumain (LEG)-cleavable antibody-drug conjugate (ADC) platform. These discussions provide valuable insights into clinical development pathways, regulatory strategies, and potential applications for addressing high unmet medical needs in oncology.

Manhattan Bio's LEG-cleavable technology directly addresses premature payload release—a critical limitation facing current-generation ADCs that often leads to off-target toxicity and narrow therapeutic windows. The company's LEG-TOP1i ADCs have demonstrated complete tumor regression with strong durability in multiple difficult-to-treat solid tumor xenograft models, representing a potentially significant advancement over certain existing ADC technologies.

"Being selected for the MSK Therapeutics Accelerator Cohort provides an exceptional opportunity to engage with world-leading clinical and translational experts," stated Zev Gechtman, Ph.D, Scientific Director at Manhattan BioSolutions. "These discussions are helping us understand how our platform's enhanced stability and tumor-selective activation could translate into meaningful improvements for patients facing difficult-to-treat malignancies."

"We are excited to welcome Manhattan BioSolutions into the cohort program," stated Eileen Flowers, PhD, Director, Technology Development & Licensing, in the Office of Entrepreneurship and Commercialization at MSK. The MSK Therapeutics Accelerator 2025 Cohort program brought together 10 innovative biotech companies with MSK investigators and commercialization strategists to explore potential collaborations for co-developing targeted cancer therapies. The program is designed to facilitate tailored mentorship with MSK faculty and provide structured introductions to MSK's translational and clinical facilities, with the goal of defining potential pathways for formal partnership through the MSK Therapeutics Accelerator. For more information about the MSK Therapeutics Accelerator, visit: https://www.mskcc.org/commercialization/programs-accelera...

About Manhattan BioSolutions
Manhattan BioSolutions, Inc., is a privately held biotechnology company focused on the development of biologic therapies targeting host defense pathways for the treatment of advanced cancers. The company advances next-generation antibody-drug conjugates (ADCs) - through collaborations with leading academic institutions. Learn more at manhattanbiosolutions.com and follow Manhattan BioSolutions on LinkedIn (https://www.linkedin.com/company/manhattanbio/) or Twitter (https://x.com/TheManhattanBio).